ASLAN Pharmaceuticals Limited (ASLN) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate ASLAN Pharmaceuticals Limited's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
-0.39
Burn Risk
P/B Ratio
-1.29
Equity Deficit
Earnings Yield
-2.57%
Yield Gap
Profitability Health
2023Return on Equity
332.81%
Strong
WeakModerateStrong
Operating Margin
-364.46%
Weak
WeakModerateStrong
Net Profit Margin
-368.50%
Weak
WeakModerateStrong
Growth Indicators
2023Revenue Growth
-
No data
Net Income Growth
13.94%
Moderate
WeakModerateStrong
EPS Growth
26.90%
Strong
WeakModerateStrong
Efficiency & Liquidity
2023Current Ratio
1.84
Moderate
WeakModerateStrong
Quick Ratio
1.84
Strong
WeakModerateStrong
Asset Turnover
0.49x
Weak
WeakModerateStrong
Inventory Turnover
-
No data
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-2.70%
Weak
WeakModerateStrong
EV / Free Cash Flow
-0.49x
Strong
WeakModerateStrong
Net Debt / EBITDA
-0.14x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
1.008
Strong
WeakModerateStrong
Return on Invested Capital
-3.23%
Weak
WeakModerateStrong
Cash Conversion Cycle
-8288.35 days
Strong
WeakModerateStrong
Fortress screener guardrails
2/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for ASLN.
View Financial Statements